biostudies-literatureWang LJTaiwan Ministry of Science and TechnologyChang Gung Memorial Hospital2260https://www.ebi.ac.uk/biostudies/studies/S-EPMC11279422biostudies-literatureUnknown16(14)We conducted a 12-week randomized double-blind placebo-controlled clinical trial to investigate the potential impact of <i>Bifidobacterium bifidum</i> (<i>Bf-688</i>) supplementation on attention-deficit/hyperactivity disorder (ADHD). Children with ADHD who were already receiving a stable dose of methylphenidate (MPH) treatment were enrolled and were randomly assigned to two groups: one receiving add-on <i>Bf-688</i> (daily bacterial count of 5 × 10⁹ CFUs) (<i>n</i> = 51) and the other receiving a placebo (<i>n</i> = 51). All participants underwent assessments using Conners' Continuous Performance Test (CPT) and Conners' Continuous Auditory Test of Attention (CATA). Additionally, fecal samples were collected at the beginning of the trial (week 0) and at the endpoint (week 12). RNutrientsAdd-On <i>Bifidobacterium Bifidum</i> Supplement in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Week Randomized Double-Blind Placebo-Controlled Clinical Trial.PMC11279422MOST 109-2314-B-182-045-MY2CMRPG8K0761CMRPG8M0031CMRPG8K0761 and CMRPG8M0031Yeh YTChou WJHuang YHLee SYDai HYLi CJTsai CSKuo HCWang LJYang CYfalseAdd-On <i>Bifidobacterium Bifidum</i> Supplement in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Week Randomized Double-Blind Placebo-Controlled Clinical Trial.We conducted a 12-week randomized double-blind placebo-controlled clinical trial to investigate the potential impact of <i>Bifidobacterium bifidum</i> (<i>Bf-688</i>) supplementation on attention-deficit/hyperactivity disorder (ADHD). Children with ADHD who were already receiving a stable dose of methylphenidate (MPH) treatment were enrolled and were randomly assigned to two groups: one receiving add-on <i>Bf-688</i> (daily bacterial count of 5 × 10⁹ CFUs) (<i>n</i> = 51) and the other receiving a placebo (<i>n</i> = 51). All participants underwent assessments using Conners' Continuous Performance Test (CPT) and Conners' Continuous Auditory Test of Attention (CATA). Additionally, fecal samples were collected at the beginning of the trial (week 0) and at the endpoint (week 12). R2024-01-01T00:00:00Z2024 Jul2026-04-08T18:42:27.198Z2025-04-19T13:12:18.477ZS-EPMC112794223906470310.3390/nu16142260